MBX Biosciences, Inc., was incorporated as an Indiana limited liability company in August 2018 and transformed into a Delaware corporation in April 2019. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for endocrine and metabolic diseases. Its R&D pipeline includes drug candidates for hypoparathyroidism, obesity and postbariatric hypoglycemia designed using its proprietary Precision Endocrine Peptide Platform. 

Expected P&L on Expiry

Key Stats

Pricing Model

About MBX20260417C30